1056999-20-2 Usage
General Description
1-(3-fluorophenyl)-1H-pyrazol-5-amine, also known as FPA, is a chemical compound with a molecular formula C9H8FN3. It belongs to the class of pyrazole compounds, which are widely used in pharmaceuticals and agrochemicals. FPA is a derivative of pyrazole and contains a fluorophenyl group, making it useful for various medicinal and chemical applications. It is known for its potential as a building block in the synthesis of novel compounds with biological activity. FPA may also be used in research and development for the discovery of new drugs and agrochemicals. Overall, this chemical compound has potential applications in the pharmaceutical and agricultural industries due to its unique structural properties and potential biological activities.
Check Digit Verification of cas no
The CAS Registry Mumber 1056999-20-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,5,6,9,9 and 9 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1056999-20:
(9*1)+(8*0)+(7*5)+(6*6)+(5*9)+(4*9)+(3*9)+(2*2)+(1*0)=192
192 % 10 = 2
So 1056999-20-2 is a valid CAS Registry Number.
1056999-20-2Relevant articles and documents
The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition
Chen, Hui,Wang, Bin,Li, Peng,Yan, Hong,Li, Gang,Huang, Haihong,Lu, Yu
supporting information, (2021/03/26)
In this study, a series of sulfonamide compounds was designed and synthesized through the systematic optimization of the antibacterial agent sulfaphenazole for the treatment of Mycobacterium tuberculosis (M. tuberculosis). Preliminary results indicate that the 4-aminobenzenesulfonamide moiety plays a key role in maintaining antimycobacterial activity. Compounds 10c, 10d, 10f and 10i through the optimization on phenyl ring at the R2 site on the pyrazole displayed promising antimycobacterial activity paired with low cytotoxicity. In particular, compound 10d displayed good activity (MIC = 5.69 μg/mL) with low inhibition of CYP 2C9 (IC50 > 10 μM), consequently low potential risk of drug-drug interaction. These promising results provide new insight into the combination regimen using sulfonamide as one component for the treatment of M. tuberculosis.
